MARY COLLIGNON: Open Payments
NPI 1194728477 · SHAFTER, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$974 in 39 payments from 16 companies in 2025. Trend: 2023 $453 · 2024 $1,287 · 2025 $974
Food & beverage: $974
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 10 | $201 |
| Corcept Therapeutics | 2 | $141 |
| Lilly USA, LLC | 4 | $132 |
| Phathom Pharmaceuticals, Inc. | 2 | $82 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $76 |
| Novo Nordisk Inc | 3 | $69 |
| AstraZeneca Pharmaceuticals LP | 3 | $47 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $32 |
| Phadia US Inc. | 1 | $25 |
Products named: Korlym, Repatha, ZEPBOUND, VOQUEZNA, CAPLYTA, OTEZLA, Ozempic, MOUNJARO.
Industry payments across CA — which companies pay providers there.
